Cutter & CO Brokerage Inc. Has $118,000 Holdings in Amarin Co. plc (NASDAQ:AMRN)

Cutter & CO Brokerage Inc. trimmed its position in Amarin Co. plc (NASDAQ:AMRN) by 16.3% in the fourth quarter, HoldingsChannel.com reports. The firm owned 240,020 shares of the biopharmaceutical company’s stock after selling 46,600 shares during the period. Cutter & CO Brokerage Inc.’s holdings in Amarin were worth $118,000 as of its most recent filing with the Securities and Exchange Commission.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AMRN. Arkfeld Wealth Strategies L.L.C. raised its holdings in shares of Amarin by 52.6% in the 4th quarter. Arkfeld Wealth Strategies L.L.C. now owns 58,000 shares of the biopharmaceutical company’s stock worth $30,000 after buying an additional 20,000 shares in the last quarter. LCM Capital Management Inc boosted its stake in Amarin by 3.1% in the 4th quarter. LCM Capital Management Inc now owns 838,259 shares of the biopharmaceutical company’s stock valued at $407,000 after buying an additional 25,100 shares in the last quarter. China Universal Asset Management Co. Ltd. grew its position in Amarin by 63.9% in the third quarter. China Universal Asset Management Co. Ltd. now owns 76,959 shares of the biopharmaceutical company’s stock valued at $48,000 after acquiring an additional 29,992 shares during the period. Kornitzer Capital Management Inc. KS raised its stake in Amarin by 80.7% during the third quarter. Kornitzer Capital Management Inc. KS now owns 95,600 shares of the biopharmaceutical company’s stock worth $60,000 after acquiring an additional 42,700 shares in the last quarter. Finally, BNP Paribas Financial Markets lifted its holdings in shares of Amarin by 8.8% during the third quarter. BNP Paribas Financial Markets now owns 1,301,468 shares of the biopharmaceutical company’s stock valued at $816,000 after acquiring an additional 104,939 shares during the period. 22.25% of the stock is owned by institutional investors.

Amarin Trading Down 1.1 %

NASDAQ AMRN opened at $0.57 on Thursday. The firm has a market cap of $234.95 million, a price-to-earnings ratio of -6.36 and a beta of 1.83. Amarin Co. plc has a 1-year low of $0.43 and a 1-year high of $1.36. The company has a 50 day moving average of $0.55 and a 200-day moving average of $0.56.

Wall Street Analyst Weigh In

Separately, StockNews.com lowered shares of Amarin from a “hold” rating to a “sell” rating in a report on Tuesday.

About Amarin

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.